Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Computational Biology Market Size & Share 2026-2035
Report ID: GMI14988
|
Published Date: November 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Computational Biology Market
Get a free sample of this reportWhat are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.

Computational Biology Market Size
The computational biology market was valued at USD 7.50 billion in 2025, is projected to reach USD 8.43 billion in 2026, and is expected to expand at a 12.5% CAGR (2026-2035) to USD 24.35 billion by 2035.
Computational Biology Market Key Takeaways
Market Leader: Certara led with over 5.6% market share in 2025.
Leading Players: Top 5 players in this market include Certara, Thermo Fisher Scientific, Schrödinger, Illumina, QIAGEN (Digital Insights), which collectively held a market share of 16% in 2025.
The computational biology market encompasses software, databases, infrastructure, and specialist services used to analyze biological data and model biological processes. Demand is shifting from isolated analytical projects toward embedded research infrastructure as pharmaceutical, biotechnology, clinical, and academic users incorporate computational methods into discovery, development, and translational research workflows.
GMI Analyst View
Based on GMI's proprietary demand-side analysis and discussions with procurement specialists and R&D leaders across leading biopharmaceutical and academic research organizations, the computational biology market registered approximately USD 6.73 billion in 2024, confirming a sustained acceleration in platform adoption through the base year. This trajectory reflects a broadening buyer base moving beyond early-adopter large pharma into mid-tier biotech and CRO procurement cycles, pointing to durable structural demand entering the forecast period.
Computational Biology Market Trends, Growth Drivers & GMI Forecast Outlook
Regulatory acceptance of in silico evidence, public investment in life-sciences research, and more capable AI models are widening the role of computational biology across the R&D cycle. Growth will depend on vendors' ability to make advanced modelling accessible despite talent, infrastructure, and data-governance constraints.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Regulatory use of physiologically based pharmacokinetic modelling is changing the commercial role of biosimulation from discretionary research support to a workflow component that can influence trial design, dosing strategy, and evidence preparation. Where modelling is integrated early, platform selection becomes tied to validation history, documentation quality, and the ability to support cross-functional work between clinical pharmacology, regulatory affairs, and development teams.
Public research funding also enlarges the market's productive base. It supports researchers, curated datasets, analytical methods, and training environments that later feed commercial development programs. This creates demand not only for institutionally priced software and services, but also for interoperable platforms that can move research outputs into translational and commercial settings.
AI-driven protein modelling and molecular design are extending computational biology into programs where experimental iteration alone would be too slow or resource intensive. The strongest demand opportunity lies with platforms that translate model output into decisions researchers can audit, rather than treating generative capability as a stand-alone feature.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
The talent constraint is particularly consequential because effective computational biology work combines molecular science, statistical modelling, and software-engineering capability. Organizations cannot readily substitute general data-science capacity for this combination. Managed platforms, API-based workflows, and specialist service providers can shorten the path from software purchase to usable scientific output, making service design an important competitive differentiator.
Data infrastructure is a separate adoption barrier. Cloud delivery can reduce the need for upfront capital investment, but it does not eliminate the operational challenge of managing large-scale sequencing datasets or optimizing computational workloads. Providers that abstract infrastructure complexity through governed, repeatable workflows are better placed to convert institutional caution into sustained use.
GMI Analyst View
We see procurement maturing from project-by-project tool selection toward decisions about durable research infrastructure. The strategic advantage will accrue to vendors that can combine scientific credibility, operational usability, and data governance rather than competing solely on model performance. This transition also raises switching costs, particularly where proprietary datasets and validated workflows become embedded in development programs.
Computational Biology Market Segment Analysis
By Tool
The computational biology market's Analysis Software & Services segment generated USD 4.35 billion in 2025 and is expected to hold 65.0% of global revenue by 2035. Its position reflects the commercial importance of enterprise discovery platforms, biosimulation suites, sequencing-analysis environments, and cloud-based bioinformatics tools. Vendors are expanding the value of installed software through integrated modules for variant analysis, protein design, and virtual modelling, enabling larger workflow-level commitments rather than incremental point-solution purchases.
Databases are projected to reach USD 4.87 billion by 2035 and accounted for 22.0% of global revenue in 2025. Curated genomic, proteomic, chemical, pathway, and clinical-outcome datasets support recurring research workflows in which data lineage, annotation quality, and interoperability are difficult to replace. The segment benefits as single-cell, spatial, and longitudinal multi-omic research generates demand for data assets that can be accessed, queried, and incorporated into reproducible analytical pipelines.
Hardware represented 20.0% of global revenue in 2025 and is forecast to grow at a 9.3% CAGR (2026-2035). Its comparatively slower expansion reflects the move toward elastic cloud compute for many bioinformatics and molecular-modelling workloads. Specialized accelerators will remain relevant for demanding simulation and AI applications, but the commercial balance is moving toward platforms that separate access to computing capacity from ownership of dedicated infrastructure.
By Application
The computational biology market's Drug Discovery & Disease Modelling segment generated USD 2.85 billion in 2025 and is expected to account for 39.0% of global revenue by 2035. Virtual screening, molecular docking, target identification, and disease-network analysis are becoming integral to early research decisions because they help teams prioritize experimental work. Adoption strengthens where platform outputs can be linked to medicinal chemistry, translational science, and portfolio-governance decisions.
Cellular & Biological Simulation is expected to reach USD 5.11 billion by 2035 and expand at a 12.0% CAGR (2026-2035). The segment is supported by mechanistic modelling of signalling pathways, metabolic systems, gene regulation, and physiological processes. Richer single-cell and spatial datasets are improving the inputs available for these models, creating greater value in applications where researchers need to assess biological response before committing to lengthy experimental programs.
Preclinical Drug Development accounted for 18.0% of global revenue in 2025 and is projected to reach USD 3.89 billion by 2035. Computational pharmacokinetic modelling, toxicity prediction, metabolic-stability analysis, and ADMET assessment are increasingly used to identify program risks earlier in development. Demand is strongest where models help research teams establish faster go/no-go decisions before expensive first-in-human studies.
Clinical Trials are expected to reach USD 3.41 billion by 2035 and grow at a 13.3% CAGR (2026-2035). Computational tools support biomarker-led patient stratification, protocol optimization, site selection, recruitment planning, and adaptive analytical approaches. Their value proposition is increasingly linked to operational execution: users require systems that can translate heterogeneous clinical and biological data into decisions that improve trial feasibility and evidence quality.
Human Body Simulation represented 9.0% of global revenue in 2025 and is expected to hold 10.0% by 2035. Whole-body pharmacokinetic models, cardiovascular simulations, and virtual planning tools address applications where direct clinical evidence can be difficult to obtain. The segment's advance depends on continued confidence in transparent, clinically interpretable models that can be reviewed by researchers, regulators, and healthcare stakeholders.
By Services
Contract services represented 58.0% of global revenue in 2025 and are projected to reach USD 15.34 billion by 2035. Outsourced bioinformatics, modelling, and managed-platform engagements offer a practical route for organizations that need advanced capability without building large internal teams. This delivery model is particularly attractive where workloads are variable, specialized expertise is scarce, or program teams need immediate access to validated computational methods.
In-house services are expected to account for 37.0% of revenue by 2035 and grow at an 11.1% CAGR (2026-2035). Large pharmaceutical and biotechnology organizations continue to invest in internal computational capabilities when proprietary data, model architecture, and scientific know-how are regarded as strategic assets. Internal execution is most compelling where computational output is tightly linked to differentiated discovery programs and cannot readily be externalized.
By End Use
Commercial end users, including pharmaceutical companies, biotechnology firms, and CROs, generated USD 5.10 billion in 2025 and are expected to hold 70.0% of global revenue by 2035. Their demand is anchored in pipeline productivity, regulatory evidence requirements, and pressure to improve the economics of discovery and development. Enterprise adoption rises when computational platforms can demonstrate a direct role in shortening decision cycles across multiple therapeutic programs.
Academics & Research Institutions are projected to reach USD 7.30 billion by 2035 and represented 32.0% of the market in 2025. These users sustain demand for bioinformatics environments, databases, high-performance computing access, and specialist analytical support. Open-source tools remain influential in this segment, but growing data intensity and reproducibility expectations create room for commercial platforms that simplify governance, collaboration, and workflow management.
GMI Analyst View
We expect integration to become as important as technical depth across the segment landscape. Buyers increasingly need continuity between discovery, biological simulation, and clinical-development decisions, which favors platforms capable of preserving data context across workflows. At the same time, broad platform adoption can create dependency risk for users, increasing the importance of open interfaces, data portability, and commercial flexibility.
Computational Biology Market Regional Analysis
North America Computational Biology Market Analysis
The computational biology market in North America generated USD 3.52 billion in 2025 and is projected to reach USD 10.22 billion by 2035. The region benefits from dense concentrations of pharmaceutical R&D, biotechnology investment, academic research capacity, specialist service providers, and regulatory expertise. Its mature buyer base creates demand for platforms that can support validated workflows, enterprise governance, and integration with established development organizations.
U.S.
The U.S. generated USD 2.99 billion in 2025 and is projected to reach USD 8.59 billion by 2035. Co-location of major pharmaceutical research organizations, computational biology developers, and regulatory institutions supports rapid translation of modelling methods into accepted development practices. Demand is reinforced by a broad base of commercial buyers seeking tools that connect proprietary data with discovery, clinical, and regulatory workflows.
Canada
Canada is expected to reach USD 1.63 billion by 2035 and grow at a 12.0% CAGR (2026-2035). Research universities, biotechnology clusters, and cross-border scientific partnerships create a supportive environment for genomics informatics and AI-enabled biological research. The market is positioned to benefit from collaborative programs that require secure access to advanced computational platforms and multi-omic data resources.
Europe Computational Biology Market Analysis
Europe is projected to reach USD 6.08 billion by 2035 and expand at an 11.6% CAGR (2026-2035). Its strengths include established pharmaceutical manufacturing, deep academic research networks, and an increasingly sophisticated regulatory environment for computational evidence. Progress will be shaped by how effectively institutions can combine cross-border research access with national data-sovereignty and privacy requirements.
Germany
Germany generated USD 365 million in 2025 and is projected to reach USD 1.03 billion by 2035. The country's pharmaceutical sector and publicly funded research institutions support demand for bioinformatics, structural biology, and systems-biology tools. Procurement is likely to favor platforms that can address both industrial discovery requirements and academically rigorous data-management standards.
UK
The UK is projected to reach USD 1.09 billion by 2035 and grow at a 12.3% CAGR (2026-2035). Strong genomics institutions and data-curation capabilities provide a valuable base for computational research and commercial platform development. Domestic demand is supported by pharmaceutical R&D and translational research, although cross-border compliance requirements continue to add operational complexity for international collaborations.
France
France represented 3.2% of global revenue in 2025 and is expected to reach USD 670 million by 2035. Its demand base combines pharmaceutical research, biotechnology activity, and structured public investment in genomic medicine and bioinformatics. Organizations that can support national research programs while meeting the needs of clinical and commercial users will be well positioned in the French market.
Asia Pacific Computational Biology Market Analysis
Asia Pacific represented 20.0% of global revenue in 2025 and is projected to reach USD 6.33 billion by 2035. Government-backed genome initiatives, expanding life-sciences R&D, and increased investment in AI-led discovery are creating a broader regional buyer base. Market development varies by country, but demand is generally moving toward cloud-delivered, localized, and scalable solutions that can support high-throughput biological research.
China
China represented 8.4% of global revenue in 2025 and is projected to reach USD 2.78 billion by 2035. National precision-medicine initiatives, domestic biotechnology development, and investment in health-related AI support rapid platform adoption. The competitive environment is also shaped by domestic suppliers pursuing localized data assets and regulatory alignment, which may alter software procurement patterns over time.
Japan
Japan is expected to reach USD 886 million by 2035 and grow at a 12.6% CAGR (2026-2035). Its established pharmaceutical sector and well-developed academic research base support demand for computational chemistry, systems biology, and biosimulation tools. Buyers are likely to prioritize platforms that combine scientific performance with reliable implementation in highly structured research and development environments.
India
India generated USD 180 million in 2025 and is projected to reach USD 1.01 billion by 2035. A growing biotechnology and CRO ecosystem, combined with strong bioinformatics and data-science capability, is supporting wider uptake of computational platforms. International drug-development partnerships and genomics initiatives are further increasing the need for interoperable tools, scalable services, and qualified analytical expertise.
South Korea
South Korea generated USD 135 million in 2025 and is projected to reach USD 507 million by 2035. Precision-medicine initiatives, biotechnology cluster development, and sustained life-sciences R&D support demand for genomics, diagnostics bioinformatics, and molecular-research tools. The market is likely to reward vendors that can align advanced analytical capability with the country's clinically oriented innovation priorities.
Latin America Computational Biology Market Analysis
Latin America is projected to reach USD 974 million by 2035 and expand at a 14.0% CAGR (2026-2035). Growth is being supported by improving biotechnology activity, pharmaceutical and CRO demand, and greater policy attention to precision medicine and genomic infrastructure. The region remains comparatively underpenetrated, creating an opportunity for cloud-based and service-led offerings that lower deployment barriers.
Brazil
Brazil represented 1.9% of global revenue in 2025 and is projected to reach USD 555 million by 2035. Biomedical research networks, genomics initiatives, and a developing domestic pharmaceutical and CRO base anchor demand. Improved connectivity and participation in international research consortia are helping institutions adopt cloud-native platforms without replicating the full infrastructure footprint of more mature markets.
MEA Computational Biology Market Analysis
MEA generated USD 187 million in 2025 and is projected to grow at a 14.6% CAGR (2026-2035). Investment in precision medicine, digital health, and national genomics programs is creating structured institutional demand, particularly in Gulf countries. Growth depends on sustained public-sector execution, the availability of specialized skills, and vendors' ability to provide secure solutions suited to developing research ecosystems.
Saudi Arabia
Saudi Arabia generated USD 47 million in 2025 and is expected to grow at a 15.4% CAGR (2026-2035). National health-transformation programs and genomics infrastructure investments are increasing demand from government research organizations and affiliated academic institutions. International collaboration can accelerate capability development, while local data-governance expectations will remain central to platform selection.
GMI Analyst View
We expect Asia Pacific to be shaped by a different demand logic from North America and Europe. Genome programs and precision-medicine investments can create policy-led platform procurement before private-sector adoption reaches comparable maturity. This favors suppliers that can pair scientific credibility with localized data practices, implementation support, and commercial models suited to large institutional programs.
Computational Biology Market Share & Competitive Landscape
The computational biology market share landscape remains fragmented, with the five leading participants collectively accounting for 16.0% of global revenue in 2025. Competitive intensity reflects the diversity of end-user needs across biosimulation, molecular modelling, genomic analysis, data management, and specialist services. Scale matters in distribution and workflow integration, but technical differentiation and scientific credibility remain important routes to market position.
Certara held 5.6% of the global market in 2025. Its competitive position is built around biosimulation software and associated regulatory and scientific services, with particular relevance in pharmacokinetic and pharmacodynamic modelling. The company benefits from deep workflow integration where model outputs must be documented, reviewed, and incorporated into development and submission processes.
Thermo Fisher Scientific held 3.8% of global revenue in 2025. Its broader life-sciences footprint provides distribution advantages across genomic analysis, proteomics informatics, and research workflows. The company is positioned to capture demand from customers seeking computational tools that can operate alongside established laboratory, sequencing, and analytical infrastructure.
Schrödinger held 3.1% of the global market in 2025. Its physics-based computational chemistry capability differentiates the company in molecular simulation, hit identification, and lead optimization. The commercial opportunity rests on combining high-value software with collaborative discovery models that link predictive capability to real-world research outcomes.
Illumina remains an important participant because bioinformatics and data-analysis services are closely connected to next-generation sequencing workflows. Its competitive relevance lies in the ability to link sequencing output with scalable analysis environments, a requirement that becomes more significant as research programs generate larger and more complex datasets.
QIAGEN Digital Insights participates through clinical genomics interpretation, knowledge bases, and bioinformatics workflows used by laboratories, pharmaceutical teams, and researchers. Its position is strengthened by demand for tools that can convert genomic data into interpretable, auditable outputs suitable for precision-medicine and biomarker applications.
Other competitors, including Dassault Systemes, DNAnexus, Genedata, Cadence, Atomwise, BenevolentAI, Compugen, Deep Genomics, Ginkgo Bioworks, Aganitha, BioDigital, Bio-Rad, Fios Genomics, Instem, and Strand Life Sciences, address specialized needs across molecular design, genomic data management, target discovery, synthetic biology, visualization, research informatics, and contract bioinformatics. Their presence reinforces a market structure in which niche expertise and domain-specific workflow fit can be as important as broad platform scale.
Recent Industry Developments
QIAGEN completed its acquisition of Genoox in May 2025, adding the Franklin cloud-based platform to its clinical genomics portfolio. The transaction strengthens QIAGEN's position in AI-enabled next-generation sequencing interpretation for laboratories seeking scalable, clinically oriented analysis workflows [5].
In November 2025, QIAGEN announced a definitive agreement to acquire Parse Biosciences. The proposed transaction would expand QIAGEN's single-cell capabilities and broaden its access to high-throughput transcriptomics workflows that can support AI-driven biological research [6].
Tempus AI completed its acquisition of Ambry Genetics in February 2025. The combination joins AI-enabled precision-medicine capabilities with clinical genetic-testing operations, extending the organization's reach across data generation, computational analysis, and clinical interpretation [7].
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →